Publications by authors named "Y Y Adar"
Article Synopsis
- The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in over seven million deaths globally, prompting the development of the BriLife vaccine by the Israel Institute for Biological Research.
- BriLife is based on a modified vesicular stomatitis virus that expresses the spike protein of SARS-CoV-2 to enhance immune response.
- A newly validated plaque assay using Vero E6 cells showed high reliability in measuring the vaccine's viral vector concentration, proving to be accurate and robust across different preparations.
Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel macrocarriers.
Front Bioeng Biotechnol
February 2024
The COVID-19 pandemic has led to high global demand for vaccines to safeguard public health. To that end, our institute has developed a recombinant viral vector vaccine utilizing a modified vesicular stomatitis virus (VSV) construct, wherein the G protein of VSV is replaced with the spike protein of SARS-CoV-2 (rVSV-ΔG-spike). Previous studies have demonstrated the production of a VSV-based vaccine in Vero cells adsorbed on Cytodex 1 microcarriers or in suspension.
View Article and Find Full Text PDFBotulism is a paralytic disease caused by botulinum neurotoxins (BoNTs). Equine antitoxin is currently the standard therapy for botulism in human. The preparation of equine antitoxin relies on the immunization of horses with botulinum toxoid, which suffers from low yield and safety limitations.
View Article and Find Full Text PDFArticle Synopsis
- - This study outlines a fast and efficient one-step purification method for the rVSV-∆G-spike vaccine against COVID-19, developed by the IIBR, testing various chromatography techniques.
- - Initial treatment of cell harvest involves endonuclease, clarification, and concentration through ultrafiltration, followed by chromatography; anion-exchange chromatography necessitates high salt for elution but shows low virus recovery.
- - The Capto Core 700 resin-based purification yields over 85% viral infectivity and effectively removes host cell proteins, meeting regulatory standards without needing an initial ultrafiltration stage.
rVSV-Spike (rVSV-S) is a recombinant viral vaccine candidate under development to control the COVID-19 pandemic and is currently in phase II clinical trials. rVSV-S induces neutralizing antibodies and protects against SARS-CoV-2 infection in animal models. Bringing rVSV-S to clinical trials required the development of a scalable downstream process for the production of rVSV-S that can meet regulatory guidelines.
View Article and Find Full Text PDF